Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post on X about recent paper Maria-Victoria Mateos and colleagues authored:
“Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial – The Lancet Oncology.”
Authors: Maria-Victoria Mateos, Meletios A Dimopoulos et al.
